Mul­ti­ple Sclero­sis Clin­i­cal Tri­als Of­fer New Treat­ments For No Cost!

Clin­i­cal Tri­als are the last stage of re­search be­fore drugs reach the mar­ket, may have bet­ter re­sults than ex­ist­ing drugs.

Los Angeles Times - - THE NATION -

The cost of life sav­ing drugs sky­rock­eted in 2016 as ev­i­dent by huge price hikes for Epi-Pen and Der­aprim. In the most ex­treme cases prices have in­creased by 100-fold and now cost peo­ple $10,000's to $100,000's and more ev­ery year.

The trend of ris­ing prices isn't show­ing signs of slow­ing down ei­ther. Medi­care sub­si­dies and in­sur­ance can't be counted on to cover the en­tire cost of new med­i­ca­tions.

Fur­ther­more, in­sur­ance de­ductibles have re­set for many at the start of 2017 along with higher rates.

As a re­sult of the ris­ing prices, clin­i­cal tri­als have be­come a more at­trac­tive op­tion for many by of­fer­ing new and ex­per­i­men­tal treat­ments at no-cost.

Clin­i­cal tri­als are an im­por­tant part of clin­i­cal re­search. In fact, many tri­als will pay par­tic­i­pants for time and travel, as well as other ben­e­fits such as free study re­lated med­i­cal care.

There are sev­eral clin­i­cal tri­als cur­rently en­rolling for MS, RRMS, and Spas­tic­ity due to MS.

Par­tic­i­pants are ur­gently needed for MS, in­clud­ing RRMS, and Spas­tic­ity due to MS con­sider par­tic­i­pat­ing in a clin­i­cal re­search study.

One of the lead­ing clin­i­cal trial providers in south­ern Cal­i­for­nia, CNS Net­work, has sev­eral en­rolling MS stud­ies. With lo­ca­tions in Gar­den Grove, Long Beach, and Tor­rance, as well as trans­porta­tion ser­vices for patients. CNS can cover the Greater Los Angeles area, North Orange County, and In­land Empire.

The ben­e­fits of par­tic­i­pat­ing in a clin­i­cal re­search study in­clude; - No in­sur­ance needed - Com­pen­sa­tion avail­able for time and travel - Op­por­tu­nity to ex­pe­ri­ence new treat­ments and drugs that may be bet­ter than what is on the mar­ket - Help re­searchers de­velop new treat­ments and po­ten­tial cures

Last year saw sev­eral major break­throughs for clin­i­cal re­search. A clin­i­cal study test­ing Ocre­lizumab for re­laps­ing mul­ti­ple sclero­sis beat ex­cep­tions and marked a major land­mark to­wards a cure. Other ad­vances for mi­graines and Alzheimer's have made ad­vances thanks to clin­i­cal re­search vol­un­teers.

To con­tinue ad­vanc­ing clin­i­cal re­search, com­pa­nies need over­come the hur­dle of re­cruit­ment-find­ing the right par­tic­i­pants. While many have heard or know of clin­i­cal tri­als, few ac­tu­ally par­tic­i­pate. With­out re­search vol­un­teers, stud­ies can't be com­pleted and po­ten­tial life-sav­ing drugs are de­layed from reach­ing mar­ket.

Newspapers in English

Newspapers from USA

© PressReader. All rights reserved.